BioSpace News Archive

Penumbra, Inc. announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below.

Akari Therapeutics, Plc announced that it has received notification from Nasdaq that Akari has been granted an additional 180-day period, or until October 23, 2023, to regain compliance with the Nasdaq minimum bid price requirement.

The Board of Directors of BD has declared a quarterly dividend of $0.91 per common share, payable on June 30, 2023 to holders of record on June 9, 2023.

The Board of Directors of PerkinElmer, Inc. declared a regular quarterly dividend of $0.07 per share of common stock.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET.

Belite Bio, Inc (NASDAQ: BLTE) today presented 18-month data from its ongoing two-year, open-label Phase 2 clinical study of Tinlarebant in adolescent STGD1 patients (“LBS-008-CT02”) as part of the poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023.

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”) announced today a national distribution agreement with Genadyne Biotechnologies Inc. for its negative pressure wound therapy (“NPWT”) systems and supplies.

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN) today presented preclinical data supporting the development of a computationally-derived amyloid-beta (Aβ) vaccine for AD at the American Academy of Neurology (AAN) 2023 Annual Meeting.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner Biogen has received U.S. Food and Drug Administration (FDA) approval of QALSODY™ (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.